Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brachytherapy | 27 | 2024 | 1220 | 6.410 |
Why?
|
Prostatic Neoplasms | 39 | 2024 | 11101 | 3.330 |
Why?
|
Androgen Antagonists | 14 | 2024 | 1412 | 1.650 |
Why?
|
Hyaluronic Acid | 3 | 2024 | 484 | 1.570 |
Why?
|
Prostate-Specific Antigen | 14 | 2024 | 2463 | 1.440 |
Why?
|
Prostatectomy | 10 | 2024 | 1786 | 1.150 |
Why?
|
Radiotherapy Dosage | 15 | 2024 | 2916 | 1.030 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2022 | 2043 | 0.820 |
Why?
|
Tumor Burden | 3 | 2024 | 1906 | 0.780 |
Why?
|
Endometrial Neoplasms | 5 | 2022 | 1382 | 0.760 |
Why?
|
Radiometry | 2 | 2024 | 818 | 0.720 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2023 | 798 | 0.720 |
Why?
|
Radiation Pneumonitis | 2 | 2018 | 100 | 0.670 |
Why?
|
Radiation Injuries | 3 | 2023 | 1198 | 0.650 |
Why?
|
Radiographic Image Enhancement | 2 | 2018 | 877 | 0.610 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 5 | 2024 | 1679 | 0.580 |
Why?
|
Organs at Risk | 2 | 2016 | 367 | 0.530 |
Why?
|
Luminescence | 1 | 2016 | 108 | 0.530 |
Why?
|
Movement | 3 | 2007 | 1490 | 0.510 |
Why?
|
Ear Neoplasms | 1 | 2016 | 118 | 0.510 |
Why?
|
Calcinosis | 3 | 2010 | 1481 | 0.510 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2016 | 99 | 0.500 |
Why?
|
Ear Canal | 1 | 2016 | 149 | 0.500 |
Why?
|
Beta Particles | 1 | 2015 | 52 | 0.500 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2021 | 1536 | 0.490 |
Why?
|
Four-Dimensional Computed Tomography | 2 | 2017 | 142 | 0.480 |
Why?
|
Parotid Gland | 1 | 2015 | 178 | 0.460 |
Why?
|
Pulmonary Fibrosis | 1 | 2018 | 506 | 0.440 |
Why?
|
Luminescent Measurements | 1 | 2015 | 342 | 0.440 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4912 | 0.420 |
Why?
|
Rectum | 3 | 2024 | 900 | 0.410 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2665 | 0.410 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 696 | 0.390 |
Why?
|
Prostate | 5 | 2024 | 1765 | 0.390 |
Why?
|
Radiotherapy | 2 | 2018 | 1502 | 0.380 |
Why?
|
Watchful Waiting | 5 | 2019 | 492 | 0.380 |
Why?
|
Tomography, X-Ray Computed | 6 | 2018 | 20760 | 0.380 |
Why?
|
Heart | 3 | 2010 | 4446 | 0.370 |
Why?
|
Radionuclide Imaging | 1 | 2015 | 2000 | 0.370 |
Why?
|
Radiation Oncology | 3 | 2022 | 572 | 0.370 |
Why?
|
Radiosurgery | 4 | 2021 | 1330 | 0.360 |
Why?
|
Retrospective Studies | 24 | 2024 | 81762 | 0.350 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2023 | 9419 | 0.340 |
Why?
|
Neoplasms, Experimental | 1 | 2015 | 1230 | 0.340 |
Why?
|
Aged | 33 | 2024 | 171504 | 0.330 |
Why?
|
Surgery, Computer-Assisted | 1 | 2016 | 1003 | 0.310 |
Why?
|
Respiration | 1 | 2015 | 1665 | 0.310 |
Why?
|
Salvage Therapy | 5 | 2023 | 1273 | 0.300 |
Why?
|
Male | 42 | 2024 | 364719 | 0.300 |
Why?
|
Healthcare Disparities | 3 | 2022 | 3415 | 0.300 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2016 | 2055 | 0.290 |
Why?
|
Hodgkin Disease | 1 | 2015 | 1384 | 0.280 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2021 | 1791 | 0.280 |
Why?
|
Magnetic Resonance Imaging | 6 | 2023 | 36743 | 0.280 |
Why?
|
Humans | 63 | 2024 | 768166 | 0.270 |
Why?
|
SEER Program | 4 | 2020 | 1444 | 0.270 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2016 | 3780 | 0.260 |
Why?
|
Artifacts | 4 | 2020 | 1926 | 0.240 |
Why?
|
Quality of Life | 2 | 2023 | 13490 | 0.240 |
Why?
|
Physical Phenomena | 1 | 2024 | 48 | 0.230 |
Why?
|
Combined Modality Therapy | 6 | 2020 | 8542 | 0.230 |
Why?
|
Survival Rate | 6 | 2020 | 12840 | 0.230 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13676 | 0.220 |
Why?
|
Middle Aged | 28 | 2024 | 223492 | 0.220 |
Why?
|
Lung Neoplasms | 3 | 2018 | 13586 | 0.220 |
Why?
|
Proportional Hazards Models | 6 | 2022 | 12543 | 0.220 |
Why?
|
Prognosis | 9 | 2024 | 30010 | 0.220 |
Why?
|
Databases, Factual | 7 | 2019 | 8080 | 0.200 |
Why?
|
Risk Assessment | 6 | 2023 | 24315 | 0.190 |
Why?
|
Atherosclerosis | 2 | 2007 | 3433 | 0.190 |
Why?
|
Belgium | 1 | 2021 | 119 | 0.190 |
Why?
|
Lung | 2 | 2017 | 10099 | 0.170 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 1232 | 0.160 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2018 | 9015 | 0.150 |
Why?
|
Urethra | 2 | 2021 | 406 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11878 | 0.150 |
Why?
|
Phantoms, Imaging | 4 | 2022 | 2512 | 0.150 |
Why?
|
ROC Curve | 1 | 2006 | 3628 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 219 | 0.150 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 710 | 0.140 |
Why?
|
Genital Neoplasms, Female | 1 | 2023 | 536 | 0.140 |
Why?
|
Neoplasm Staging | 7 | 2021 | 11244 | 0.140 |
Why?
|
Cervix Uteri | 1 | 2021 | 577 | 0.140 |
Why?
|
Disease-Free Survival | 3 | 2017 | 6847 | 0.140 |
Why?
|
Acceleration | 2 | 2007 | 189 | 0.140 |
Why?
|
Carcinoma, Endometrioid | 1 | 2019 | 275 | 0.140 |
Why?
|
Algorithms | 4 | 2018 | 14164 | 0.130 |
Why?
|
Propensity Score | 3 | 2021 | 1969 | 0.130 |
Why?
|
Androgens | 1 | 2024 | 1281 | 0.130 |
Why?
|
Urethral Stricture | 1 | 2016 | 50 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2021 | 3556 | 0.130 |
Why?
|
Follow-Up Studies | 6 | 2020 | 39348 | 0.130 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2149 | 0.120 |
Why?
|
Feasibility Studies | 2 | 2023 | 5315 | 0.120 |
Why?
|
Vagina | 1 | 2020 | 850 | 0.110 |
Why?
|
Morbidity | 1 | 2019 | 1755 | 0.110 |
Why?
|
Cohort Studies | 7 | 2021 | 41754 | 0.110 |
Why?
|
Logistic Models | 5 | 2019 | 13290 | 0.110 |
Why?
|
Survival Analysis | 4 | 2019 | 10101 | 0.110 |
Why?
|
Regression Analysis | 2 | 2015 | 6340 | 0.110 |
Why?
|
Neoplasms, Second Primary | 1 | 2021 | 1061 | 0.110 |
Why?
|
Female | 18 | 2023 | 397192 | 0.110 |
Why?
|
Time Factors | 3 | 2021 | 40218 | 0.110 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 2907 | 0.110 |
Why?
|
Radiotherapy, Conformal | 1 | 2016 | 549 | 0.110 |
Why?
|
Treatment Outcome | 6 | 2020 | 65371 | 0.100 |
Why?
|
Tidal Volume | 1 | 2015 | 518 | 0.100 |
Why?
|
Adult | 13 | 2023 | 223646 | 0.100 |
Why?
|
Travel | 1 | 2018 | 805 | 0.100 |
Why?
|
Kinetics | 2 | 2019 | 6329 | 0.100 |
Why?
|
Prospective Studies | 5 | 2023 | 54926 | 0.100 |
Why?
|
Fellowships and Scholarships | 1 | 2020 | 1135 | 0.100 |
Why?
|
Sample Size | 1 | 2015 | 846 | 0.100 |
Why?
|
Consensus | 1 | 2021 | 3212 | 0.090 |
Why?
|
Reproducibility of Results | 3 | 2018 | 20227 | 0.090 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1673 | 0.090 |
Why?
|
Disease Management | 2 | 2019 | 2536 | 0.090 |
Why?
|
Patient Compliance | 1 | 2020 | 2697 | 0.090 |
Why?
|
Cochlea | 1 | 2016 | 848 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2862 | 0.080 |
Why?
|
Catheters | 2 | 2023 | 427 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2021 | 14729 | 0.080 |
Why?
|
Mice, Nude | 1 | 2015 | 3623 | 0.080 |
Why?
|
Papillomavirus Infections | 1 | 2021 | 1640 | 0.080 |
Why?
|
Aged, 80 and over | 9 | 2020 | 59629 | 0.080 |
Why?
|
Boston | 1 | 2021 | 9374 | 0.070 |
Why?
|
United States | 7 | 2022 | 73039 | 0.070 |
Why?
|
Area Under Curve | 1 | 2010 | 1643 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3239 | 0.070 |
Why?
|
Filtration | 1 | 2006 | 229 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2846 | 0.060 |
Why?
|
Health Services Accessibility | 2 | 2020 | 5520 | 0.060 |
Why?
|
Observer Variation | 1 | 2010 | 2622 | 0.060 |
Why?
|
User-Computer Interface | 1 | 2010 | 1407 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10399 | 0.060 |
Why?
|
Research Design | 1 | 2019 | 6211 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8054 | 0.050 |
Why?
|
Registries | 1 | 2019 | 8375 | 0.050 |
Why?
|
Piroxicam | 1 | 2002 | 18 | 0.050 |
Why?
|
Odds Ratio | 3 | 2020 | 9669 | 0.050 |
Why?
|
Recurrence | 1 | 2015 | 8509 | 0.050 |
Why?
|
Child, Preschool | 2 | 2015 | 42669 | 0.050 |
Why?
|
Rhodamines | 1 | 2002 | 178 | 0.050 |
Why?
|
Risk Factors | 2 | 2019 | 74944 | 0.050 |
Why?
|
Polyglycolic Acid | 1 | 2002 | 408 | 0.050 |
Why?
|
Information Storage and Retrieval | 1 | 2006 | 830 | 0.040 |
Why?
|
Internship and Residency | 1 | 2020 | 5953 | 0.040 |
Why?
|
Colposcopy | 1 | 2021 | 151 | 0.040 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 3252 | 0.040 |
Why?
|
Radioisotopes | 1 | 2021 | 517 | 0.040 |
Why?
|
Carcinosarcoma | 1 | 2020 | 108 | 0.040 |
Why?
|
Delphi Technique | 1 | 2023 | 891 | 0.040 |
Why?
|
Mice | 2 | 2016 | 82029 | 0.040 |
Why?
|
Needles | 1 | 2022 | 461 | 0.040 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2020 | 218 | 0.040 |
Why?
|
Selection Bias | 1 | 2020 | 360 | 0.040 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 17140 | 0.040 |
Why?
|
Young Adult | 2 | 2015 | 60066 | 0.040 |
Why?
|
Linear Models | 1 | 2007 | 5884 | 0.040 |
Why?
|
Calcium | 1 | 2010 | 5792 | 0.040 |
Why?
|
Lactic Acid | 1 | 2002 | 1140 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6526 | 0.030 |
Why?
|
Child | 2 | 2015 | 80917 | 0.030 |
Why?
|
Adolescent | 2 | 2015 | 89169 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2019 | 592 | 0.030 |
Why?
|
Education | 1 | 2019 | 533 | 0.030 |
Why?
|
Software | 1 | 2010 | 4478 | 0.030 |
Why?
|
Cryotherapy | 1 | 2017 | 164 | 0.030 |
Why?
|
Heart Rate | 1 | 2007 | 4214 | 0.030 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2020 | 480 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 300 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2020 | 714 | 0.030 |
Why?
|
Polymers | 1 | 2002 | 1630 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2923 | 0.030 |
Why?
|
HeLa Cells | 1 | 2021 | 3074 | 0.030 |
Why?
|
Myocardium | 1 | 2007 | 4788 | 0.030 |
Why?
|
Infant | 1 | 2016 | 36535 | 0.030 |
Why?
|
Biocompatible Materials | 1 | 2002 | 1702 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2017 | 427 | 0.030 |
Why?
|
Triage | 1 | 2021 | 997 | 0.030 |
Why?
|
Animals | 2 | 2016 | 169246 | 0.030 |
Why?
|
Testosterone | 1 | 2024 | 2491 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 3814 | 0.030 |
Why?
|
Community Health Centers | 1 | 2017 | 469 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2021 | 1967 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2006 | 4063 | 0.030 |
Why?
|
Neoplasms | 1 | 2021 | 22371 | 0.030 |
Why?
|
Taxoids | 1 | 2015 | 667 | 0.020 |
Why?
|
Forced Expiratory Volume | 1 | 2017 | 1831 | 0.020 |
Why?
|
Markov Chains | 1 | 2015 | 979 | 0.020 |
Why?
|
Models, Economic | 1 | 2015 | 719 | 0.020 |
Why?
|
Patient Selection | 1 | 2022 | 4260 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1422 | 0.020 |
Why?
|
Societies, Medical | 1 | 2021 | 3968 | 0.020 |
Why?
|
Population Surveillance | 1 | 2019 | 2596 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 21206 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2021 | 3620 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3620 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8741 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6669 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2784 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2015 | 2008 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3533 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9613 | 0.010 |
Why?
|
Clinical Competence | 1 | 2020 | 4858 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2015 | 2603 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12077 | 0.010 |
Why?
|
Genomics | 1 | 2019 | 5926 | 0.010 |
Why?
|
Chemistry, Physical | 1 | 2002 | 153 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5536 | 0.010 |
Why?
|
Chemical Phenomena | 1 | 2002 | 486 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18412 | 0.010 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2002 | 944 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13671 | 0.010 |
Why?
|
Microspheres | 1 | 2002 | 788 | 0.010 |
Why?
|
Particle Size | 1 | 2002 | 1649 | 0.010 |
Why?
|